Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung... Purpose Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients. Methods A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively. Results A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups. Conclusions SMI add-on therapy appeared to be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/effects-of-shengmai-injection-add-on-therapy-to-chemotherapy-in-2lxm54qqx0
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
DOI
10.1007/s00520-018-4167-4
Publisher site
See Article on Publisher Site

Abstract

Purpose Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients. Methods A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively. Results A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups. Conclusions SMI add-on therapy appeared to be

Journal

Supportive Care in Cancer – Springer Journals

Published: Mar 29, 2018

References

  • Cancer statistics, 2015
    Siegel, RL; Miller, KD; Jemal, A
  • Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship
    Molina, JR; Yang, P; Cassivi, SD; Schild, SE; Adjei, AA
  • Lung cancer: current therapies and new targeted treatments
    Hirsch, FR; Scagliotti, GV; Mulshine, JL; Kwon, R; Curran, WJ; Wu, YL; Paz-Ares, L
  • Non-small cell lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology
    Ettinger, DS; Wood, DE; Aisner, DL; Akerley, W; Bauman, J; Chirieac, LR; D’Amico, TA; DeCamp, MM; Dilling, TJ; Dobelbower, M; Doebele, RC; Govindan, R; Gubens, MA; Hennon, M; Horn, L; Komaki, R; Lackner, RP; Lanuti, M; Leal, TA; Leisch, LJ; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Stevenson, J; Swanson, SJ; Tauer, K; Yang, SC; Gregory, K; Hughes, M
  • Recent advances in the management of non-small cell lung cancer
    Shojaee, S; Nana-Sinkam, P
  • Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients
    Jiao, L; Dong, C; Liu, J; Chen, Z; Zhang, L; Xu, J; Shen, X; Che, J; Yang, Y; Huang, H; Li, H; Sun, J; Jiang, Y; Mao, Z; Chen, P; Gong, Y; Jin, X; Xu, L
  • Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients
    Han, Y; Wang, H; Xu, W; Cao, B; Han, L; Jia, L; Xu, Y; Zhang, Q; Wang, X; Zhang, G; Yu, M; Yang, G
  • Traditional Chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial
    Jiang, Y; Liu, LS; Shen, LP; Han, ZF; Jian, H; Liu, JX; Xu, L; Li, HG; Tian, JH; Mao, ZJ
  • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    Moher, D; Liberati, A; Tetzlaff, J; Altman, DG
  • Karnofsky performance status revisited: reliability, validity, and guidelines
    Schag, CC; Heinrich, RL; Ganz, PA
  • Doublet chemotherapy for advanced non-small cell lung cancer
    Ramalingam, S; Belani, CP
  • Reporting results of cancer treatment
    Miller, AB; Hoogstraten, B; Staquet, M; Winkler, A
  • Shengmai injection treatment for chemotherapy-reduced adverse reaction in non-small cell lung cancer 30 cases of patients
    Zhou, GF; Li, AJ
  • Clinical observation of Shengmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer
    Li, GX
  • Shengmai injection combined with gemcitabine plus cisplatin cure advanced NSCLC
    Wang, R; Wang, ZX; Wang, QC
  • Clinical study on the treatment of advanced NSCLC with Shengmai injection combined with chemotherapy
    Liang, CW
  • Clinical observation of Shengmai injection combined chemotherapy in advanced lung cancer
    Yao, JT; Wang, YZ; Zhang, YJ; Wu, HM; Zhao, Z
  • Clinical observation of adjunctive treatment with Shengmai injection in non small cell lung cancer
    Zhang, QH
  • The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer
    Sun, DB; Han, Y
  • The effect on quality of life to advanced stage non-small cell lung cancer patient treated with Shengmai injection combined chemotherapy
    Chen, QS; Chen, Y; Yang, ZJ; Liu, JB; Pei, RQ
  • Effect of Shengmai injection combined with chemotherapy on the quality of life and immune function in patients with advanced non-small cell lung cancer
    Lu, XA
  • Effect of Shengmai injection on the quality of life of patients with advanced non-small cell lung cancer receiving chemotherapy
    Bao, YH
  • Shengmai injection combined with NP regimen in the treatment of 30 cases of advanced non-small cell lung cancer
    Yang, ZJ; Deng, CM; Qiu, YH; Mo, BS
  • Clinical observation of Shengmai injection combined with chemotherapy in the treatment of middle to advanced lung cancer
    Wu, Q; He, X
  • Efficacy of Shengmai injection combined with TP regimen in the treatment of advanced non-small cell lung cancer
    Wang, DJ
  • Clinical efficacy of Shengmai injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
    Liu, JY; Liu, BY; Liu, Y
  • Effect of Shengmai injection combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer
    Zhang, CM
  • Effect of chemotherapy on quality of life in patients with non-small cell lung cancer
    Mannion, E; Gilmartin, JJ; Donnellan, P; Keane, M; Waldron, D
  • Pharmacological action and clinical application of Shengmai injection
    Li, Q; Liu, H